Taiwan · Delayed Price · Currency is TWD PharmaEngine Statistics
Total Valuation
PharmaEngine has a market cap or net worth of TWD 7.92 billion. The enterprise value is 3.24 billion.
| Market Cap | 7.92B |
| Enterprise Value | 3.24B |
Important Dates
The next estimated earnings date is Tuesday, May 12, 2026.
| Earnings Date | May 12, 2026 |
| Ex-Dividend Date | Aug 13, 2025 |
Share Statistics
PharmaEngine has 143.68 million shares outstanding. The number of shares has increased by 0.01% in one year.
| Current Share Class | 143.68M |
| Shares Outstanding | 143.68M |
| Shares Change (YoY) | +0.01% |
| Shares Change (QoQ) | +0.21% |
| Owned by Insiders (%) | 1.25% |
| Owned by Institutions (%) | 6.08% |
| Float | 93.43M |
Valuation Ratios
The trailing PE ratio is 20.48 and the forward PE ratio is 19.96.
| PE Ratio | 20.48 |
| Forward PE | 19.96 |
| PS Ratio | 8.69 |
| PB Ratio | 1.61 |
| P/TBV Ratio | 1.61 |
| P/FCF Ratio | 4.59 |
| P/OCF Ratio | 4.58 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 7.44, with an EV/FCF ratio of 1.88.
| EV / Earnings | 8.36 |
| EV / Sales | 3.56 |
| EV / EBITDA | 7.44 |
| EV / EBIT | 7.62 |
| EV / FCF | 1.88 |
Financial Position
The company has a current ratio of 27.17, with a Debt / Equity ratio of 0.01.
| Current Ratio | 27.17 |
| Quick Ratio | 26.90 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | 0.10 |
| Debt / FCF | 0.02 |
| Interest Coverage | 3,060.87 |
Financial Efficiency
Return on equity (ROE) is 7.51% and return on invested capital (ROIC) is 141.49%.
| Return on Equity (ROE) | 7.51% |
| Return on Assets (ROA) | 4.84% |
| Return on Invested Capital (ROIC) | 141.49% |
| Return on Capital Employed (ROCE) | 8.58% |
| Weighted Average Cost of Capital (WACC) | 5.57% |
| Revenue Per Employee | 20.25M |
| Profits Per Employee | 8.61M |
| Employee Count | 45 |
| Asset Turnover | 0.17 |
| Inventory Turnover | 1.52 |
Taxes
In the past 12 months, PharmaEngine has paid 121.65 million in taxes.
| Income Tax | 121.65M |
| Effective Tax Rate | 23.89% |
Stock Price Statistics
The stock price has decreased by -37.32% in the last 52 weeks. The beta is 0.25, so PharmaEngine's price volatility has been lower than the market average.
| Beta (5Y) | 0.25 |
| 52-Week Price Change | -37.32% |
| 50-Day Moving Average | 59.54 |
| 200-Day Moving Average | 68.07 |
| Relative Strength Index (RSI) | 37.05 |
| Average Volume (20 Days) | 369,189 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, PharmaEngine had revenue of TWD 911.42 million and earned 387.64 million in profits. Earnings per share was 2.69.
| Revenue | 911.42M |
| Gross Profit | 859.56M |
| Operating Income | 425.46M |
| Pretax Income | 509.29M |
| Net Income | 387.64M |
| EBITDA | 427.21M |
| EBIT | 425.46M |
| Earnings Per Share (EPS) | 2.69 |
Balance Sheet
The company has 4.72 billion in cash and 42.12 million in debt, with a net cash position of 4.67 billion or 32.54 per share.
| Cash & Cash Equivalents | 4.72B |
| Total Debt | 42.12M |
| Net Cash | 4.67B |
| Net Cash Per Share | 32.54 |
| Equity (Book Value) | 4.93B |
| Book Value Per Share | 34.28 |
| Working Capital | 4.90B |
Cash Flow
In the last 12 months, operating cash flow was 1.73 billion and capital expenditures -280,000, giving a free cash flow of 1.73 billion.
| Operating Cash Flow | 1.73B |
| Capital Expenditures | -280,000 |
| Depreciation & Amortization | 1.75M |
| Net Borrowing | -8.45M |
| Free Cash Flow | 1.73B |
| FCF Per Share | 12.02 |
Margins
Gross margin is 94.31%, with operating and profit margins of 46.68% and 42.53%.
| Gross Margin | 94.31% |
| Operating Margin | 46.68% |
| Pretax Margin | 55.88% |
| Profit Margin | 42.53% |
| EBITDA Margin | 46.87% |
| EBIT Margin | 46.68% |
| FCF Margin | 189.44% |
Dividends & Yields
This stock pays an annual dividend of 2.00, which amounts to a dividend yield of 3.72%.
| Dividend Per Share | 2.00 |
| Dividend Yield | 3.72% |
| Dividend Growth (YoY) | 300.00% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 222.35% |
| Buyback Yield | -0.01% |
| Shareholder Yield | 3.67% |
| Earnings Yield | 4.90% |
| FCF Yield | 21.81% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on July 26, 2017. It was a forward split with a ratio of 1.1999616012.
| Last Split Date | Jul 26, 2017 |
| Split Type | Forward |
| Split Ratio | 1.1999616012 |
Scores
PharmaEngine has an Altman Z-Score of 34.37 and a Piotroski F-Score of 5.
| Altman Z-Score | 34.37 |
| Piotroski F-Score | 5 |